ArticleCureus2025
Beyond Traditional Risk Factors: Inflammation, Asymmetric Dimethylarginine, and N-Terminal pro-B-Type Natriuretic Peptide Predict Cardiovascular Risk in Chronic Kidney Disease.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCardiovascular disease (CVD) is the leading cause of morbidity and mortality in chronic kidney disease (CKD). While traditional risk factors such as hypertension and diabetes are highly prevalent, they fail to fully explain the disproportionate cardiovascular (CV) burden. Non-traditional mechanisms, including inflammation, endothelial dysfunction, oxidative stress, and metabolic disturbances, are increasingly recognized.
objectiveThe objective of this study is to evaluate the prevalence and interplay of traditional and non-traditional CV risk factors in CKD, with a focus on biomarkers (IL-6, asymmetric dimethylarginine (ADMA), homocysteine, uric acid) and echocardiographic findings, and to determine their ability to predict N-terminal pro-brain natriuretic peptide (NT-proBNP) levels.
methodsWe conducted a cross-sectional study of 100 CKD patients (stages I-V), of whom 21 (21%) were on hemodialysis. Demographic, clinical, laboratory, and echocardiographic data were collected. Biomarkers (IL-6 and homocysteine in all patients; ADMA in 52 patients) were measured. Correlation and multivariable regression analyses were used to identify predictors of NT-proBNP and echocardiographic abnormalities.
resultsThe cohort (60% male, mean BMI 27.4 kg/m²) showed a high prevalence of hypertension (83%) and diabetes (57%). Non-traditional biomarkers were frequently elevated: IL-6 (mean 23.5 pg/mL), homocysteine (mean 28.8 µmol/L), ADMA (mean 189.4 ng/mL), and uric acid (mean 8.5 mg/dL). Valvular calcifications were present in 52% of patients. NT-proBNP was markedly elevated (mean 10,912 pg/mL) and showed significant correlations with IL-6 (r = 0.211, p = 0.002) and ADMA (r = 0.334, p < 0.001). In multivariable regression analysis, both IL-6 (β = 0.207, p = 0.039) and ADMA (β = 0.385, p = 0.005) independently predicted NT-proBNP, with ADMA demonstrating the strongest effect. Hyperhomocysteinemia correlated with valvular calcifications, while uric acid was associated with hypertension and reduced eGFR.
conclusionBoth traditional and non-traditional factors contribute to the CV burden in CKD. Biomarkers of inflammation and endothelial dysfunction (IL-6, ADMA) are independent predictors of NT-proBNP and provide prognostic value beyond classical determinants. Incorporating these biomarkers into risk stratification models may improve prediction and guide innovative therapeutic strategies to reduce CV morbidity and mortality in CKD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.